Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Author(s):

Félix Guerrero-Ramos, MD, PhD, FEBU ,Srikala Sridhar, MD

Key Takeaways

Multidisciplinary teams should integrate oncologists and urologists, emphasizing patient-centered care for high-risk non–muscle-invasive bladder cancer.
Global preparation involves understanding diverse market needs and ensuring access to resources and education.
Comprehensive training on new therapies and evolving treatment landscapes is essential before product launches.
Attention to potential adverse events, such as immune-related reactions, is crucial for prelaunch preparation.

Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP: 9.Exploring Emerging Data in NMIBC

Now Viewing

EP: 10.Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

What does an ideal multidisciplinary team look like in BCG-naive, high-risk non–muscle-invasive bladder cancer? How can the team (oncologists & urologists) prepare globally (in different markets) to set up patients for the most success?
What education or resources are needed prior to the launch of these products or prior to this evolving landscape to prepare for the launches?
What adverse events need attention and education as part of the prelaunch preparation?
Closing thoughts from each of the panelists.